Castle Biosciences Stock Analysis

CSTL Stock  USD 27.09  0.57  2.15%   
Castle Biosciences is undervalued with Real Value of 30.91 and Target Price of 33.0. The main objective of Castle Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Castle Biosciences is worth, separate from its market price. There are two main types of Castle Biosciences' stock analysis: fundamental analysis and technical analysis.
The Castle Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

Castle Stock Analysis Notes

About 95.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Castle Biosciences had not issued any dividends in recent years. Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. The company was founded in 2007 and is headquartered in Friendswood, Texas. Castle Biosciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 482 people. For more info on Castle Biosciences please contact Derek Maetzold at 866 788 9007 or go to https://castlebiosciences.com.

Castle Biosciences Quarterly Total Revenue

85.78 Million

Castle Biosciences Investment Alerts

Castle Biosciences generated a negative expected return over the last 90 days
Castle Biosciences has high historical volatility and very poor performance
The company reported the previous year's revenue of 219.79 M. Net Loss for the year was (57.47 M) with profit before overhead, payroll, taxes, and interest of 105.03 M.
Castle Biosciences currently holds about 273.17 M in cash with (5.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.39.
Castle Biosciences has a poor financial position based on the latest SEC disclosures
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from zacks.com: SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder

Castle Biosciences Upcoming and Recent Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Castle Largest EPS Surprises

Earnings surprises can significantly impact Castle Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-03-08
2020-12-31-0.12-0.17-0.0541 
2021-05-10
2021-03-31-0.23-0.170.0626 
2021-11-08
2021-09-30-0.4-0.47-0.0717 
View All Earnings Estimates

Castle Biosciences Environmental, Social, and Governance (ESG) Scores

Castle Biosciences' ESG score is a quantitative measure that evaluates Castle Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Castle Biosciences' operations that may have significant financial implications and affect Castle Biosciences' stock price as well as guide investors towards more socially responsible investments.

Castle Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Nuveen Asset Management, Llc2024-09-30
542.6 K
Palisade Capital Management Llc2024-09-30
502.3 K
Point72 Asset Management, L.p.2024-09-30
499.2 K
Jacobs Levy Equity Management, Inc.2024-09-30
496.5 K
Renaissance Technologies Corp2024-09-30
489.6 K
Granahan Investment Management Inc..2024-09-30
425.2 K
Kornitzer Capital Management Inc2024-09-30
407.2 K
Morgan Stanley - Brokerage Accounts2024-09-30
396.9 K
Ameriprise Financial Inc2024-09-30
349.2 K
Blackrock Inc2024-06-30
M
Wasatch Advisors Lp2024-09-30
1.8 M
Note, although Castle Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Castle Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 758.72 M.

Castle Profitablity

The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.06 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.06.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.17)(0.18)
Return On Capital Employed(0.17)(0.18)
Return On Assets(0.13)(0.13)
Return On Equity(0.15)(0.14)

Management Efficiency

The value of Return On Tangible Assets is estimated to slide to -0.18. The value of Return On Capital Employed is expected to slide to -0.18. At this time, Castle Biosciences' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 2.8 M this year, although the value of Net Tangible Assets will most likely fall to about 181.4 M. Castle Biosciences' management efficiency ratios could be used to measure how well Castle Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for Next Year
Book Value Per Share 14.60  8.66 
Tangible Book Value Per Share 10.22  7.20 
Enterprise Value Over EBITDA(10.99)(11.54)
Price Book Value Ratio 1.48  1.55 
Enterprise Value Multiple(10.99)(11.54)
Price Fair Value 1.48  1.55 
Enterprise Value223.1 M198.4 M
Understanding the operational decisions made by Castle Biosciences management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin
0.0592
Profit Margin
0.0195
Beta
0.985
Return On Assets
(0)
Return On Equity
0.0147

Technical Drivers

As of the 20th of December, Castle Biosciences shows the Mean Deviation of 2.44, risk adjusted performance of (0.02), and Standard Deviation of 3.29. Castle Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Castle Biosciences market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Castle Biosciences is priced correctly, providing market reflects its regular price of 27.09 per share. Given that Castle Biosciences has information ratio of (0.05), we suggest you to validate Castle Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.

Castle Biosciences Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Castle Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Castle Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Castle Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Castle Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Castle Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Castle Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Frank Stokes over a week ago
Acquisition by Frank Stokes of 14617 shares of Castle Biosciences subject to Rule 16b-3
 
Derek Maetzold over a month ago
Disposition of 299 shares by Derek Maetzold of Castle Biosciences at 34.15 subject to Rule 16b-3
 
Olson Tiffany over a month ago
Acquisition by Olson Tiffany of 830 shares of Castle Biosciences subject to Rule 16b-3
 
Derek Maetzold over two months ago
Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 28.734 subject to Rule 16b-3
 
Derek Maetzold over three months ago
Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 29.457 subject to Rule 16b-3
 
Derek Maetzold over three months ago
Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 30.024 subject to Rule 16b-3
 
Oelschlager Kristen M over three months ago
Disposition of 1250 shares by Oelschlager Kristen M of Castle Biosciences at 29.969 subject to Rule 16b-3
 
Derek Maetzold over three months ago
Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 30.049 subject to Rule 16b-3
 
Derek Maetzold over three months ago
Disposition of 169 shares by Derek Maetzold of Castle Biosciences at 30.089 subject to Rule 16b-3
 
Bradbury Daniel over three months ago
Disposition of 1431 shares by Bradbury Daniel of Castle Biosciences at 26.647 subject to Rule 16b-3
 
Frank Stokes over three months ago
Acquisition by Frank Stokes of 9744 shares of Castle Biosciences subject to Rule 16b-3
 
Oelschlager Kristen M over three months ago
Disposition of 4225 shares by Oelschlager Kristen M of Castle Biosciences at 23.77 subject to Rule 16b-3

Castle Biosciences Outstanding Bonds

Castle Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Castle Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Castle bonds can be classified according to their maturity, which is the date when Castle Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Castle Biosciences Predictive Daily Indicators

Castle Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Castle Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Castle Biosciences Corporate Filings

F4
19th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
17th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
11th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
9th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
5th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
19th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
13th of November 2024
An amended filing to the original Schedule 13G
ViewVerify

Castle Biosciences Forecast Models

Castle Biosciences' time-series forecasting models are one of many Castle Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Castle Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Castle Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Castle Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Castle shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Castle Biosciences. By using and applying Castle Stock analysis, traders can create a robust methodology for identifying Castle entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.26)(0.27)
Operating Profit Margin(0.31)(0.32)
Net Loss(0.26)(0.27)
Gross Profit Margin 0.80  0.63 

Current Castle Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Castle analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Castle analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
33.0Strong Buy9Odds
Castle Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Castle analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Castle stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Castle Biosciences, talking to its executives and customers, or listening to Castle conference calls.
Castle Analyst Advice Details

Castle Stock Analysis Indicators

Castle Biosciences stock analysis indicators help investors evaluate how Castle Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Castle Biosciences shares will generate the highest return on investment. By understating and applying Castle Biosciences stock analysis, traders can identify Castle Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow122.9 M
Common Stock Shares Outstanding26.8 M
Total Stockholder Equity391.3 M
Tax Provision119 K
Quarterly Earnings Growth Y O Y-0.926
Property Plant And Equipment Net37.7 M
Cash And Short Term Investments243.1 M
Cash98.8 M
Accounts Payable10.3 M
Net Debt-83.5 M
50 Day M A31.1652
Total Current Liabilities47.7 M
Other Operating Expenses287.8 M
Non Current Assets Total157.7 M
Non Currrent Assets Other2.6 M
Stock Based Compensation51.2 M
When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.93)
Earnings Share
0.21
Revenue Per Share
11.34
Quarterly Revenue Growth
0.395
Return On Assets
(0)
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.